408 related articles for article (PubMed ID: 31759735)
1. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
2. Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017-2018.
Vila-Córcoles A; Ochoa-Gondar O; de Diego-Cabanes C; Satué-Gracia EM; Torras-Vives V; Forcadell-Peris MJ; Ribas-Seguí D; Vila-Rovira A; Rodríguez-Casado C
Vaccine X; 2023 Apr; 13():100264. PubMed ID: 36798107
[TBL] [Abstract][Full Text] [Related]
3. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
[TBL] [Abstract][Full Text] [Related]
4. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study.
Heo JY; Seo YB; Choi WS; Kim EJ; Jeong HW; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Song JY
J Infect Dis; 2022 Mar; 225(5):836-845. PubMed ID: 34537847
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial.
Juergens C; de Villiers PJ; Moodley K; Jayawardene D; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Hum Vaccin Immunother; 2014; 10(5):1343-53. PubMed ID: 24576885
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
12. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
[TBL] [Abstract][Full Text] [Related]
13. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017.
Vila-Córcoles A; Ochoa-Gondar O; de Diego C; Satué E; Vila-Rovira A; Aragón M
Euro Surveill; 2019 Jul; 24(29):. PubMed ID: 31339099
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine.
Hsiao A; Hansen J; Timbol J; Lewis N; Isturiz R; Alexander-Parrish R; McLaughlin JM; Gessner BD; Klein NP
JAMA Netw Open; 2022 Mar; 5(3):e221111. PubMed ID: 35302634
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; El Sahly HM; George S; Winokur P; Edwards K; Brady RC; Rouphael N; Keitel WA; Mulligan MJ; Burton RL; Nakamura A; Ferreria J; Nahm MH
Vaccine; 2018 Jan; 36(5):606-614. PubMed ID: 29279281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
